Natera (NasdaqGS:NTRA) announced a strategic expansion of its Board of Directors with the appointment of Monica Bertagnolli. This decision occurred against a backdrop of significant market volatility, ...

What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 5.2% in the afternoon session after stocks ...

RBC Capital analyst Conor McNamara initiated coverage of Natera (NTRA) with an Outperform rating and $251 price target The firm says Natera is ...

Genetic testing company Natera (NASDAQ:NTRA). reported Q4 CY2024 results , with sales up 53% year on year to $476.1 million.

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

Natera has a twelve month low of $83.13 and a twelve month high of $183.00. The stock has a 50-day simple moving average of $165.61 and a two-hundred day simple moving average of $148.09.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the ...

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish ...

BTIG analyst Mark Massaro maintained a Buy rating on Natera (NTRA – Research Report) today and set a price target of $190.00. The company’s ...

Shares of Natera stock opened at $140.66 on Wednesday. The stock has a market cap of $19.02 billion, a price-to-earnings ratio of -79.92 and a beta of 1.80. The company has a debt-to-equity ratio ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the HEROES clinical trial. HEROES is a multi-center ...